M. Gray

Lipidomics Profiling and Risk of Coronary Artery Disease in the BioHEART-CT Discovery Cohort

S. Grieve, P. Meikle, G. Figtree, 2023, Biomolecules.

Incorporating a Polygenic Risk Score-Triaged Coronary Calcium Score into Cardiovascular Disease Examinations to Identify SubClinicAL coronAry arTEry Disease (ESCALATE): Protocol for a Prospective, Non-Randomised Implementation Trial.

S. Grieve, G. Figtree, T. Usherwood, 2023, American heart journal.

Protocol for the Stimulating β3-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease

A. Keech, S. Grieve, G. Figtree, 2021, BMJ Open.

Serum Soluble Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 (sLOX-1) Is Associated with Atherosclerosis Severity in Coronary Artery Disease.

S. Grieve, G. Figtree, Jean Y. H. Yang, 2023, Biomolecules.

Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors

Deepak L. Bhatt, P. Ellinor, A. Keech, 2023, Journal of the American College of Cardiology.

Improving clinical outcomes for patients with coronary artery disease despite no standard modifiable cardiovascular risk factors (SMuRF): not out of the woods yet.

M. Gray, G. A. Figtree, 2024, European heart journal.

Primary prevention of cardiovascular disease in women

M. Gray, G. A. Figtree, B. Vogel, 2024, Climacteric : the journal of the International Menopause Society.

Genetic testing in cardiovascular disease

M. Gray, Elizabeth N Robertson, G. A. Figtree, 2024, The Medical journal of Australia.